



SAFETY DATA SHEET

Revision date 16-Jun-2025

Version 3

Page 1 / 14

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Levetiracetam Injection (Hospira, Inc.)
Product Code(s) PZ03336
Trade Name: Not applicable
Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used for electrolyte replacement

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous.

OSHA Classification

Hazards not otherwise classified (HNOC)
Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200
Not applicable

2.2. Label elements

Signal word Not classified

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 2 / 14
Version 3

Hazard statements

Not classified in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
+ ACETIC ACID (CAS #: 64-19-7)	**		200-580-7 (607-002-00-6)	Flam. Liq. 3 (H226) Skin Corr. 1A (H314)	Eye Irrit. 2 :: 10%≤C<25% Skin Corr. 1A :: C≥90% Skin Corr. 1B :: 25%≤C<90% Skin Irrit. 2 :: 10%≤C<25%	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
Levetiracetam (CAS #: 102767-28-2)	10		Not Listed	Not classified	Not classified	No data available	No data available
SODIUM CHLORIDE (CAS #: 7647-14-5)	*	-	231-598-3	Not classified	Not classified	No data available	No data available
Sodium acetate	**		Not Listed	Not classified	Not classified	No data	No data

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 3 / 14
Version 3

trihydrate (CAS #: 6131-90-4)						available	available
----------------------------------	--	--	--	--	--	-----------	-----------

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Levetiracetam 102767-28-2	> 5000	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3550	10000	No data available	No data available	No data available
+ ACETIC ACID 64-19-7	3310	1060	11.4	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration $\geq 0.1\%$ (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

+ Substance with a Union workplace exposure limit

* Proprietary

** to adjust pH

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
--	--

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians	None.
---------------------------	-------

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 4 / 14
Version 3

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as mists) may fuel fires/explosions.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Not applicable.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions No special precautions are needed in handling this material.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 5 / 14
Version 3

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

SODIUM CHLORIDE

Latvia	TWA: 5 mg/m ³ ;
Russia	MAC: 5 mg/m ³

+ ACETIC ACID

ACGIH TLV	TWA: 10 ppm STEL: 15 ppm
Austria	TWA-TMW: 10 ppm; TWA-TMW: 25 mg/m ³ ; STEL-KZGW: 20 ppm (8 X 5 min); STEL-KZGW: 50 mg/m ³ (8 X 5 min);
Bulgaria	TWA: 25 mg/m ³ ; TWA: 10 ppm; STEL: 50 mg/m ³ ; STEL: 20 ppm;
Czech Republic	25 mg/m ³
Denmark	Ceiling: 50 mg/m ³ TWA: 10 ppm; TWA: 25 mg/m ³ ; STEL: 50 mg/m ³ ; STEL: 20 ppm;
Estonia	TWA: 10 ppm; TWA: 25 mg/m ³ ; STEL: 10 ppm; STEL: 25 mg/m ³ ;
European Union	TWA: 25 mg/m ³ ; TWA: 10 ppm; STEL: 50 mg/m ³ ; STEL: 20 ppm;
Finland	TWA: 5 ppm; TWA: 13 mg/m ³ ; STEL: 10 ppm; STEL: 25 mg/m ³ ;
France	25 mg/m ³
Germany DFG	TWA-MAK: 10 ppm; I(2); TWA-MAK: 25 mg/m ³ ; I(2); Peak: 20 ppm; Peak: 50 mg/m ³ ;
Germany TRGS	TWA-AGW; 10 ppm (exposure factor 2); TWA-AGW; 25 mg/m ³ (exposure factor 2);
Hungary	TWA-AK: 10 ppm; TWA-AK: 25 mg/m ³ ; STEL-CK: 20 ppm; STEL-CK: 50 mg/m ³ ;
Ireland	TWA: 10 ppm;

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 6 / 14
Version 3

	TWA: 25 mg/m ³ ; STEL: 20 ppm; STEL: 50 mg/m ³ ;
Italy MDLPS	TWA: 25 ppm; TWA: 10 mg/m ³ ; STEL: 50 mg/m ³ ; STEL: 20 ppm;
Latvia	TWA: 10 ppm; TWA: 25 mg/m ³ ; STEL: 50 mg/m ³ ; STEL: 20 ppm;
Netherlands	TWA: 10 ppm; TWA: 25 mg/m ³ ; STEL: 20 ppm; STEL: 50 mg/m ³ ;
Poland	TWA-NDS: 25 mg/m ³ ; STEL-NDSCh: 50 mg/m ³ ;
Romania	TWA: 10 ppm; TWA: 25 mg/m ³ ; STEL: 20 ppm; STEL: 50 mg/m ³ ;
Russia	MAC: 5 mg/m ³
Slovakia	Skin TWA: 10 ppm; TWA: 25 mg/m ³ ; Ceiling: 50 mg/m ³ ;
Spain	TWA-(VLA-ED): 10 ppm; TWA-(VLA-ED): 25 mg/m ³ ; STEL (VLA-EC): 20 ppm; STEL (VLA-EC): 50 mg/m ³ ;
Switzerland	TWA-MAK: 10 ppm; TWA-MAK: 25 mg/m ³ ; STEL-KZGW: 20 ppm; STEL-KZGW: 50 mg/m ³ ;
OSHA PEL	TWA: 10 ppm TWA: 25 mg/m ³ (vacated) TWA: 10 ppm (vacated) TWA: 25 mg/m ³
United Kingdom	TWA: 10 ppm; TWA: 25 mg/m ³ ; STEL: 20 ppm; STEL: 50 mg/m ³ ;

Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Levetiracetam

Pfizer Occupational Exposure Band (OEB): B-OEB 1 (control exposure to the range of $\geq 10000 \mu\text{g/day}$)

SODIUM CHLORIDE

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of $1000\mu\text{g/m}^3$ to $3000\mu\text{g/m}^3$)

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 7 / 14
Version 3

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

Thermal hazards

No information available.

Environmental exposure controls

No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Appearance

Solution

Physical state

Liquid

Color

Clear, colorless

Odor

No information available.

Odor threshold

No information available

Property

Values

Melting point / freezing point

No data available

Boiling point or initial boiling point and boiling range

No data available

Flammability (solid, gas)

No data available

Lower and upper explosion limit/flammability limit

Lower explosion limit

No data available

Upper explosion limit

No data available

Flash point

No data available

Autoignition temperature

No data available

Decomposition temperature

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 8 / 14
Version 3

SADT (°C)	No data available
pH	5.5
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	No data available
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

9.2. Other information

Molecular formula	Mixture
Molecular weight	Mixture

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity	No information available.
------------	---------------------------

10.2. Chemical stability

Stability	Stable under normal conditions.
-----------	---------------------------------

Explosion data

Sensitivity to mechanical impact	No information available.
Sensitivity to static discharge	No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions	No information available.
------------------------------------	---------------------------

10.4. Conditions to avoid

Conditions to avoid	Fine particles (such as dust and mists) may fuel fires/explosions.
---------------------	--

10.5. Incompatible materials

Incompatible materials	As a precautionary measure, keep away from strong oxidizers.
------------------------	--

10.6. Hazardous decomposition products

Hazardous decomposition products	No data available.
----------------------------------	--------------------

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:	The information included in this section describes the potential hazards of the individual ingredients
Short term	Mild eye irritant in experimental animals (based on components)
Acute toxicity	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 9 / 14
Version 3

Skin corrosion/irritation Based on available data, the classification criteria are not met.
Respiratory or skin sensitization Based on available data, the classification criteria are not met.
STOT - single exposure Based on available data, the classification criteria are not met.
STOT - repeated exposure Based on available data, the classification criteria are not met.
Reproductive toxicity Based on available data, the classification criteria are not met.
Germ cell mutagenicity Based on available data, the classification criteria are not met.
Carcinogenicity Based on available data, the classification criteria are not met.
Aspiration hazard Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Levetiracetam

Rat Oral LD50 > 5000 mg/kg
Rat Para-periosteal LD50 > 1000 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³
Rat Oral LD 50 3 g/kg
Mouse Oral LD 50 4 g/kg
Rabbit Dermal LD 50 > 10 g/kg

+ ACETIC ACID

Mouse Sub-tenon injection (eye) LC 50 5620 ppm/1H
Rat Oral LD 50 3310 mg/kg
Rabbit Dermal LD 50 1060 uL/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
SODIUM CHLORIDE	= 3550 mg/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat) 1 h
+ ACETIC ACID	= 3310 mg/kg (Rat)	= 1060 mg/kg (Rabbit)	= 11.4 mg/L (Rat) 4 h

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild
Eye irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Levetiracetam

6 Month(s) Rat Oral >= 50 mg/kg/day LOAEL Liver, Kidney, Central nervous system
13 Week(s) Mouse Oral 60 mg/kg/day NOAEL Liver

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Levetiracetam

Reproductive & Fertility Rat Oral 70 mg/kg/day NOAEL Fetotoxicity, Embryotoxicity
Reproductive & Fertility Rat Oral 1800 mg/kg/day NOAEL Fertility
Embryo / Fetal Development Rat Oral 3600 mg/kg/day NOAEL Maternal Toxicity
Embryo / Fetal Development Rat Oral 1200 mg/kg/day NOAEL Fetotoxicity
Embryo / Fetal Development Rabbit Oral 200 mg/kg/day LOAEL Maternal Toxicity
Embryo / Fetal Development Rabbit Oral 200 mg/kg/day NOAEL Embryotoxicity
Peri-/Postnatal Development Rat Oral 1800 mg/kg/day NOAEL Maternal Toxicity, Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Levetiracetam

In Vitro Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vitro HGPRT Forward Gene Mutation Assay Chinese Hamster Ovary (CHO) cells Negative
In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 10 / 14
Version 3

In Vivo Micronucleus Mouse Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Levetiracetam

80 Week(s) Mouse Oral 960 mg/kg/day NOAEL Not carcinogenic

104 Week(s) Rat Oral 1800 mg/kg/day NOAEL Not carcinogenic

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Releases to the environment should be avoided. Environmental properties of the formulation have not been investigated.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

+ ACETIC ACID

Fathead Minnow NPDES LC-50 96 hours 88 mg/L

Bluegill Sunfish NPDES LC-50 96 hours 75 mg/L

Goldfish NPDES LC-50 24 hours 423 mg/L

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	Not PBT/vPvB PBT assessment does not apply
+ ACETIC ACID	Not PBT/vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 11 / 14
Version 3

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

Levetiracetam

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4

SODIUM CHLORIDE

CERCLA/SARA Section 313 de minimus %	Not Listed
---	------------

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 12 / 14
Version 3

California Proposition 65	Not Listed
TSCA	Present
EINECS	231-598-3
AICS	Present
Sodium acetate trihydrate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present
+ ACETIC ACID	
CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	200-580-7
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6 Schedule 2

National regulations

France

Occupational Illnesses (R-463-3, France)

Chemical name	French RG number
SODIUM CHLORIDE 7647-14-5	RG 78

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

Chemical name	Number	Class
+ ACETIC ACID 64-19-7	5.2.5	Class II

TRGS 905

Not applicable

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable

Storage of Hazardous Material Not applicable

WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20 Not applicable

Major Accidents Ordinance SR 814.012 Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
+ ACETIC ACID 64-19-7	75	-

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 13 / 14
Version 3

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

EU - Plant Protection Products (1107/2009/EC)

Chemical name	EU - Plant Protection Products (1107/2009/EC)
SODIUM CHLORIDE 7647-14-5	Plant protection agent
+ ACETIC ACID 64-19-7	Plant protection agent

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
SODIUM CHLORIDE 7647-14-5	Product-type 1: Human hygiene
+ ACETIC ACID 64-19-7	Product-type 2: Disinfectants and algicides not intended for direct application to humans or animals Simplified procedure - Category 1

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
KECL - Korean Existing Chemicals Inventory
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances
NZIoC - New Zealand Inventory of Chemicals
TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H314 - Causes severe skin burns and eye damage. H226 - Flammable liquid and vapor.

Data Sources: Publicly available toxicity information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the

SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 14 / 14
Version 3

Company/Undertaking.

Revision date 16-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.